Ask about this productRelated genes to: RALY Blocking Peptide
- Gene:
- RALY NIH gene
- Name:
- RALY heterogeneous nuclear ribonucleoprotein
- Previous symbol:
- -
- Synonyms:
- P542, HNRPCL2
- Chromosome:
- 20q11.22
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-21
- Date modifiied:
- 2016-10-05
Related products to: RALY Blocking Peptide
Related articles to: RALY Blocking Peptide
- The heterogeneous nuclear ribonucleoprotein-associated protein Raly plays a role in regulating cell proliferation and metabolism in eukaryotic nerve cells. However, the biological significance of Raly in oligodendrocyte lineage progression has not been previously explored. In this study, we found that Raly expression decreased during maturation of oligodendrocyte lineage cells. Knockdown of Raly in primary oligodendrocyte progenitor cells cultured in differentiation medium resulted in a significant increase in myelin-related proteins myelin basic protein and MAG. Furthermore, injection of an adenovirus expressing Raly shRNA into the subventricular zone of mice promoted oligodendrocyte progenitor cell differentiation, restored white matter integrity, and ameliorated cognitive deficits in the bilateral common carotid artery stenosis and senescence model. We further investigated the mechanism by which Raly regulates oligodendrocyte progenitor cell differentiation. Downregulation of Raly in primary oligodendrocyte progenitor cells led to increased mRNA and protein levels of Sox10, a pivotal player in oligodendrocyte development. The stability of Sox10 mRNA was unaffected by Raly downregulation, and RNA immunoprecipitation assays showed no binding between Raly and Sox10 mRNA. Dual luciferase and chromatin immunoprecipitation assays revealed that Raly downregulated the transcription of Sox10 by binding to a site located 1200 bp upstream of the Sox10 start codon. Collectively, our findings suggest that Raly plays a crucial role in oligodendrocyte progenitor cell differentiation and negatively regulates Sox10. These results may provide new insights into therapeutic strategies for neurological disorders associated with hypomyelination. - Source: PubMed
Publication date: 2026/06/20
Zhang ZhiShu XinSun LiangLi ChenggangGao ShenghanXia ShengnanShao PengfeiBao XinyuXu YuhaoXu Yun - The oncoprotein c-Myc is frequently dysregulated in human cancers, yet the underlying mechanisms remain elusive. Here, we identify the RNA-binding protein RALY as a critical post-translational stabilizer of c-Myc. RALY homodimerizes and acts as a scaffold to bridge the deubiquitinating enzyme USP22 to c-Myc, thereby preventing c-Myc ubiquitination and proteasomal degradation. Under physiological growth factor stimulation, RALY is phosphorylated by Akt at S106 and T160. This phosphorylation event enables ternary complex formation with USP22 and c-Myc, promoting c-Myc stabilization and driving RALY's oncogenic activity. Furthermore, a synthetic peptide derived from RALY, termed RAMi, disrupts the RALY-USP22-c-Myc complex, destabilizes c-Myc, and exhibits potent anti-tumor effects. Together, these findings reveal Akt-mediated RALY phosphorylation as a molecular switch governing c-Myc stability and underscore the therapeutic potential of targeting the RALY-USP22-c-Myc axis in cancer. - Source: PubMed
Publication date: 2026/05/29
Yu NingZhao KailiangWu XianningYao BoGuo XiaoruiTang SuyunHu HaoWang ZhongyuWang NingMei Yide - The RNA-binding protein RALY is an important member of the heterogeneous nuclear ribonucleoproteins (hnRNPs). It can target and regulate the key links of the RNA metabolic networks, such as RNA alternative splicing and stability maintenance, and is deeply involved in biological processes such as cell proliferation, metabolic reprogramming, and exosome biogenesis. RALY functions as a core regulator in tumorigenesis and tumor progression. In recent years, studies on RALY in cancer have been increasing. It is abnormally highly expressed in hepatocellular carcinoma, colorectal cancer, lung cancer, and other tumors. Emerging evidence suggests its oncogenic functions, multiple regulatory mechanisms, and potential clinical translational value, providing a candidate target for tumor precision therapy. At the mechanism level, RALY mainly plays a role in promoting cancer by regulating the three core methods of target gene alternative splicing, post-translational modifications (PTMs) of itself (ubiquitination, glycosylation, etc.), and mediating tumor metabolic reprogramming, thereby driving malignant biological behaviors such as tumor cell proliferation, invasion, metastasis, and chemotherapy resistance. At the clinical level, high RALY expression is associated with poor patient prognosis, indicating that it may serve as a promising candidate prognostic marker. This article reviews the molecular structure and core functions of RALY, focuses on its regulatory mechanisms and clinical significance in various tumors, and discusses the prospects and challenges of targeting RALY so as to provide theoretical support and direction for basic research and clinical translation of RALY-related tumors. - Source: PubMed
Publication date: 2026/04/22
Huang JialeJia LizhouLiu YuexinGao LingnaWeng ZhihuiLi Yanmei - Transfer RNA-derived fragments (tRFs) are emerging regulators in cancer, yet their role in the development and progression of gastric cancer (GC) remains unclear. Through RNA sequencing technology, this study identified a tRNA-derived fragment, tRF-3005a, that is significantly upregulated in GC tissues and cell lines and is associated with poor prognosis. Functionally, it promotes the proliferation, migration, and invasion of GC cells. Mechanistically, tRF-3005a bound to RALY, enhancing its interaction with SPAG4 mRNA, suppressing exon 8 skipping and leading to an increased generation of oncogenic SPAG4-L isoforms, thereby activating GRB14/PI3K/AKT signaling and ultimately promoting GC progression. This study reveals a novel mechanism wherein tRF-3005a promotes gastric cancer development by regulating RALY-mediated alternative splicing of SPAG4 to activate the GRB14/PI3K/AKT pathway, suggesting it may serve as a prognostic biomarker and therapeutic target. - Source: PubMed
Publication date: 2026/03/24
Cui HuaipingYuan YancongYin YizheGao RuihongLiu ZhaodongPeng LipanWang JinshenWang ZhuSong TingtingLiu Jinglei - Sichuan Shelduck, a unique Chinese indigenous duck breed, exhibits superior meat quality traits, but its genetic basis has not been systematically evaluated. This study assessed meat quality traits, including pH, color, shear force, moisture, and intramuscular fat (IMF) in 240 Sichuan Shelducks (123 males and 117 females). At 90 days, males exhibited higher IMF (2.83% ± 0.58 vs. 2.79% ± 0.63, P < 0.01) and moisture content (76.35% ± 1.04 vs. 75.68% ± 2.3, P < 0.01), but lower shear force (31.00 ± 9.11 N), compared with females (33.32 ± 10.03 N). Phenotypic correlation analysis revealed that moisture content was positively correlated with flesh color and tenderness. SNP-based heritability estimates were moderate to high for moisture (0.42), meat lightness (L*, 0.39), and IMF (0.34). Genome-wide association studies (GWAS) identified 29 significant SNPs for IMF on chromosome 21, with the peak SNP (chr21:2210804 T > C) near STK4 explaining 19.68% of the phenotypic variance. GO functional analysis results speculated that STK4 may be involved in adipocyte differentiation through the FoxO/MAPK pathway. Transcriptomic analysis of pectoral muscle with high versus low IMF highlighted enrichment of DGAT2 in Glycerolipid metabolism and PPAR signaling pathways. Regression analysis prioritized RALY for its role in cholesterol homeostasis. These candidate genes (STK4, DGAT2, RALY) and associated molecular markers provide a genetic basis for improving Sichuan Shelduck meat quality in breeding programs. - Source: PubMed
Publication date: 2026/02/06
Yang ZhaoXi YangQi JingjingBai LiliZhang JunLv JiaLi BoLi LiangLiu Hehe